This thematic series published in Journal of Hematology & Oncology is focused on novel agents, first-in-human studies, and regimens for different cancer types.
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
New advances in the design and manufacture of monoclonal antibodies, bispecific T cell engagers, and antibody-drug conjugates make the antibody-directed agents more powerful with less toxicities. Small molecul...
Citation: Journal of Hematology & Oncology 2019 12:113